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Introduction: Depression is a multifactorial mood disorder with a high
prevalence worldwide. Until now, treatments for depression have focused
on the inhibition of monoaminergic reuptake sites, which augment the
bioavailability of monoamines in the CNS. Advances in drug discovery have
widened the therapeutic options with the synthesis of so-called selective
serotonin reuptake inhibitors (SSRIs), such as fluoxetine.
Areas covered: The aim of this case history is to describe and discuss the
pharmacokinetic and pharmacodynamic profiles of fluoxetine, including its
acute effects and the adaptive changes induced after long-term treatment.
Furthermore, the authors review the effect of fluoxetine on neuroplasticity
and adult neurogenesis. In addition, the article summarises the preclinical
behavioural data available on fluoxetine’s effects on depressive-like behav-
iour, anxiety and cognition as well as its effects on other diseases. Finally,
the article describes the seminal studies validating the antidepressant effects
of fluoxetine.
Expert opinion: Fluoxetine is the first selective SSRI that has a recognised
clinical efficacy and safety profile. Since its discovery, other molecules that
mimic its mechanism of action have been developed, commencing a new
age in the treatment of depression. Fluoxetine has also demonstrated utility
in the treatment of other disorders for which its prescription has now been
approved.
Keywords: antidepressant, depression, fluoxetine, selective serotonin reuptake inhibitor,
serotonin
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1. Introduction
Major depression disorder (MDD) is a mental disorder that affects > 350 million
people of all ages, with the highest proportion of cases occurring between 25 and
34 years of age. According to the World Health Organization, depression is
projected to become the second leading contributor to the global burden of disease
by the year 2020 [1]. MDD is diagnosed according to the symptoms described in the
Diagnostic Manual and Statistical of Mental Disorders, and the first-line therapy for
depression involves the use of antidepressants that principally act by inhibiting
monoamine reuptake. In this review, we describe the discovery, assays, development
and some aspects of the clinical use of fluoxetine. This compound has for decades
been the most commonly prescribed selective serotonin reuptake inhibitor (SSRI).
It was launched for the treatment of depression at the end of the 1980s, and its clin-
ical used has since been expanded to other disorders. Moreover, other compounds
with a similar mechanism of action have also been developed and introduced into
clinical practice.
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In the early twentieth century, depression was identified as
‘melancholia’, and it was mainly treated with barbiturates and
amphetamines. It was not until the 1950s when the first two
compounds with more potent antidepressant activity were
developed, named antidepressants. They are iproniazid, the
first monoamine oxidase inhibitor (MAOI), and imipramine,
the first tricyclic antidepressant (TCA). The emergence of
these two antidepressant drugs revolutionised psychiatry and
the pharmaceutical industry. Indeed, the discovery of these
new treatments for MDD led to the development of new
theories about the pathophysiology of the mood disorder.
Ten years later, other TCAs were synthesised (amitriptyline,
nortriptyline, desipramine and clomipramine), some of which
are still in use to treat depression and other pathologies. By
contrast, the intolerance and side effects observed in patients
treated with MAOIs (nephrotoxicity and hypertension) lim-
ited the prescription of MAOIs and there is a strong decline
in their use.
In 1965, the monoaminergic hypothesis of depression was
postulated [2], which implicated noradrenergic and serotonin-
ergic dysfunction in depression. As a result, some pharmaceu-
tical companies focused their research on the search for new
drugs that specifically target 5-HT reuptake. Thus, an SSRI
was developed by Eli Lilly and Company, the compound
numbered LY110140 (fluoxetine) was initially approved as a
drug for medical use in Belgium in 1986, although it was
not approved by the FDA until 1987, under the name of
Prozac. Numerous clinical trials reported that the antide-
pressant efficacy of fluoxetine was as potent as the TCA but
with fewer side effects due to its selective profile [3]. However,
some adverse effects are associated with fluoxetine, which
could limit the treatment adherence, and not all patients
reached the desired therapeutic response after fluoxetine treat-
ment. However, this antidepressant drug was a breakthrough
in the treatment of depression, being prescribed since the
1980s; indeed its clinical use has been extended even to
other pathologies.
Finally, it must be taken into account that fluoxetine
treatment has a delayed onset of therapeutic action requiring
several weeks to achieve a sustained increase in monoamine
levels, which produces adaptive changes and the subsequent
antidepressant effect. According to the monoaminergic
hypothesis, an acute monoamine increase should produce an
immediate antidepressant response but sadly this does not
happen. This fact calls into question this hypothesis of depres-
sion, leading to propose other underlying mechanisms that
might explain the antidepressant effect of fluoxetine such as
neurotrophic factors and other novel target molecules cited
in the present review.
2. Biochemistry
Fluoxetine (Lilly 110140: 3-(p-trifluoromethylphenoxy)-N-
methyl-3-phenylpropylamine) is an SSRI (Figure 1) that exists
as a racemic molecule, with the R(-) and S(+) enantiomers
showing equal potency as inhibitors of 5-hydroxytryptamine
(5-HT) uptake in both in vitro and in vivo uptake assays [4].
Moreover, fluoxetine is metabolised by N-demethylation to
norfluoxetine, which is an active metabolite. Norfluoxetine
also acts as an SSRI but with a stronger potency than the
parental compound [5]. This active metabolite also exists in
an enantiomeric form, but unlike fluoxetine enantiomers,
S-norfluoxetine is over 20-fold more potent in inhibiting
5-HT uptake than the (R)-enantiomer [6].
3. Pharmacokinetic properties
The pharmacokinetic parameters of fluoxetine reveal it to be
efficiently absorbed from the rat gastrointestinal tract after
oral administration. Due to hepatic first-pass metabolism, the
oral bioavailability is < 90% [7]. Fluoxetine has a high
lipophilic profile, and it appears to bind strongly to plasma pro-
tein, which means it is widely distributed. Thus, high concen-
trations of fluoxetine and its metabolite norfluoxetine reach
the brain. Early studies with fluoxetine in humans using radio-
active isotopes showed that about 75% of the radioactivity was
excreted in the urine and 10% was recovered in the faeces over
the following 30 days. Fluoxetine is converted metabolically to
norfluoxetine and other metabolites (Figure 2) [8], and CYP
Article highlights.
. Fluoxetine is a selective serotonin reuptake inhibitor that
increases the concentration of 5-hydroxytryptamine
(5-HT) in many brain areas without affecting other
neurotransmitter receptors.
. Fluoxetine and its active metabolite norfluoxetine have a
long half-life, which is considered to be advantageous,
given that it minimises withdrawal.
. Chronic fluoxetine treatment induces adaptive changes
in serotoninergic systems, such as the desensitisation of
5-HT autoreceptors.
. Fluoxetine can enhance neuroplasticity and augment
adult neurogenesis.
. In general, preclinical behavioural studies show that
chronic but not acute fluoxetine administration improves
depressive-like behaviour, anxiety and cognition.
. Clinical trials have validated the antidepressant efficacy
and safety of fluoxetine to treat depression, and its use
for other pathologies has been approved.
. Fluoxetine inhibits the CYP isozymes and might
potentiate drug interactions.
This box summarises key points contained in the article.
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Figure 1. Chemical structure of fluoxetine (LY110140).
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isozymes play an essential role in the clearance of both fluoxe-
tine and norfluoxetine. Furthermore, both compounds
inhibited CYP2D6 isozymes in vitro and in vivo. The (S)-enan-
tiomers of fluoxetine and norfluoxetine are six times more
potent than both (R)-enantiomers (Figure 2) [9], and therefore,
both compounds can compete with other drugs for their metab-
olism by CYP2D6, which would explain their potential to
participate in pharmacokinetic drug interactions [9].
In addition, fluoxetine and norfluoxetine have a long
half-life, and the half-life of the active metabolite is being lon-
ger. Indeed, the plasma elimination half-life in humans was
1 -- 3 for fluoxetine and 7 -- 15 days for norfluoxetine [10].
This long half-life could be considered as an advantage for
fluoxetine because it avoids the induction of withdrawal
syndrome when it is necessary to suppress or change the med-
ication. By contrast, it must be kept in mind that fluoxetine
inhibits CYP2D6 and potentiates drug interactions.
4. Pharmacodynamic profile
4.1 Inhibition of monoamine uptake
The first in vitro study of fluoxetine kinetics showed that this
compound selectivity inhibited 5-HT uptake into synapto-
somes isolated from whole rat brain with a Ki of 5.2  10-8
M, whereas the inhibition constant for the blockade of nor-
adrenaline uptake was 1  10-5 M and that for dopamine
uptake was 1.5 10-5M [11]. Subsequent in vitro uptake studies
confirmed the strong capacity of fluoxetine to inhibit 5-HT
uptake, greater than its affinity for other monoamines (Table 1)
[12,13].
In vivo uptake studies into rat brain synaptosomes also
demonstrated that acute fluoxetine administration produced
a significant reduction in 5-HT uptake (57%) compared
with controls but not that of noradrenaline or dopa-
mine [11,13]. The brain regions with the most pronounced
reduction in 5-HT uptake were the cerebral cortex and
brainstem, whereas fluoxetine administration failed to inhibit
uptake into synaptosomes in cerebellum [13]. In vivo studies
were carried out to evaluate the duration of the effects of
fluoxetine on 5-HT uptake inhibition, demonstrating that
maximal inhibition occurred after 4 h and that uptake was
restored to normal levels 48 h after administration of fluoxe-
tine. However, throughout this time course, the uptake of
noradrenaline was unaltered by fluoxetine administration [13].
The effect of fluoxetine was long lasting compared with the
time course of other antidepressants, which could reflect the
extremely long half-life of both fluoxetine and its active
metabolite, norfluoxetine [14]. Overall, these data suggest
that the metabolite plays an important role for the therapeutic
effect of fluoxetine.
4.2 Transporters and receptors binding
Several competitive binding assays with monoamine transport-
ers showed that fluoxetine presents a strong affinity for the
5-HT transporter and only a weak or no affinity for the nor-
adrenaline and dopamine transporters, respectively [12,15,16].
Therefore, these data confirmed the 5-HT selective profile of
this compound. Furthermore, fluoxetine showed relatively
weak affinity for 5-HT receptors, as measured by radioligand
binding to the 5-HT1 (A, B, C and D), 5-HT2 and 5-HT3
R-Fluoxetine
S-Fluoxetine
R-Norfluoxetine
S-Norfluoxetine
Inactive
metabolites
Norfluoxetine
glucuronide
Fluoxetine
glucuronide
Excretion
Liver
CYP2D6C
YP2C9
CYP2C1
9
CYP3A
Figure 2. Schematic representation of fluoxetine metabolism pathway.
Fluoxetine
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subtypes, although the strongest affinity was found for 5-HT2
receptors [5,12,17]. Additional studies were carried out to evalu-
ate the interaction of fluoxetine with other neurotransmitters
receptors, with radioligand-binding assays showing that fluox-
etine has low affinity for D1 and D2 dopaminergic, a- and
b-adrenergic, muscarinic cholinergic and histamine H1 recep-
tors (Table 2) [5,12]. On the contrary, TCA present a greater
affinity for several neurotransmitters receptors, which con-
ferred them a side-effect profile, worsening the antidepressant
therapy. Thus, their affinity for muscarinic cholinergic recep-
tors may induce blurred vision, dry mouth, constipation, uri-
nary retention, seizures or memory impairment;
histaminergic receptor antagonism can produce sedation or
drowsiness and the blockade of a1-adrenergic receptors is asso-
ciated with cardiotoxicity effects, including tachycardia, ortho-
static hypotension and dizziness. Overall, these findings are
consistent with the lack of fluoxetine’s side effects, which
were often observed with TCA drugs. However, fluoxetine
also has adverse effects, affecting the patient compliance and
treatment adherence. Thereby, fluoxetine often causes nausea,
diarrhoea, loss of appetite and sexual dysfunction. Addition-
ally, it could be accompanied by other negative effects such
as insomnia, anxiety or even may induce the so-called
‘serotonin syndrome’, characterised by specific symptoms
including agitation, mental confusion, hyperthermia, arrhyth-
mia, diarrhoea and tremor.
4.3 Acute fluoxetine
Microdialysis studies revealed that acute fluoxetine adminis-
tration enhances extracellular 5-HT levels, in conjunction
with a decrease in both the synthesis and turnover of 5-HT
in the raphe nuclei [18]. An increase in 5-HT has also been
reported in other brain regions, such as the frontal cortex,
striatum, diencephalon or hippocampus [18-21]. In particular,
it should be note that the 5-HT increase in the frontal cortex
by acute fluoxetine treatment is smaller than that in the raphe
nuclei [22,23]. This could reflect the activation of somatoden-
dritic 5-HT1A autoreceptors provoked by the large increase
in 5-HT in the raphe nuclei, which may negatively control
cell firing and 5-HT release into terminal areas including
the frontal cortex [24,25]. This issue arose in microdialysis
and electrophysiological studies with 5-HT1A antagonists.
Unlike other SSRI, fluoxetine also increases dopamine and
noradrenaline concentrations in the prefrontal cortex, as
measured by microdialysis [15,17]. It was suggested that this
effect might reflect an interaction with the 5-HT2C receptor,
and indeed, it has been demonstrated that fluoxetine acts as
a 5-HT2C receptor antagonist due to its relative affinity for
this receptor [26]. This receptor subtype exerts inhibitory
control on both ventral tegmental dopaminergic and locus
coeruleus noradrenergic neurons [27]. Thus, the ability of
fluoxetine to block 5-HT2C receptor is the most plausible
explanation for the cortical increase in catecholamines. Other
microdialysis studies indicated that fluoxetine increases nor-
adrenaline and dopamine in the hypothalamus and ventral
tegmental area, respectively [28,29], whereas it does not change
the extracellular levels of these transmitters in brain areas such
as the striatum or nucleus accumbens [30,31].
4.4 Long-term fluoxetine
Chronic fluoxetine treatment induces a persistent increase in
5-HT levels in several brain regions, such as the diencepha-
lon, striatum, hippocampus and frontal cortex [19,32,33], with-
out altering those of cortical noradrenaline and
dopamine [34,35]. Initially, it was suggested that sustained
5-HT enhancement was caused by the simple accumulation
of higher plasma levels of fluoxetine or its metabolite, because
they have a long half-life. However, this would appear to be
unlikely given that residual drug was still present and the
enhanced extracellular 5-HT levels were promptly restored
after acute treatment [19,32]. Thus, several adaptive mecha-
nisms associated with 5-HT neurotransmission have been
Table 1. In vitro binding affinities of fluoxetine for the
inhibition of catecholamine uptake and for serotonin,
noradrenaline and dopamine transporters.
Binding affinity and
inhibition uptake
Ki (M)
[3H]-5-HT uptake synaptosomes
rat brain [11]
5.2  10-8
[3H]-Noradrenaline uptake
synaptosomes rat brain [11]
1  10-5
[3H]-Dopamine uptake
synaptosomes rat brain [11]
1.5  10-5
[3H]-Citalopram in vitro binding
rat cortex [12]
2.0 ± 0.1  10-9
[3H]-Nisoxetine in vitro binding
rat cortex [12]
4.7 ± 0.1  10-7
[3H]-Citalopram in vitro binding
human transfected cells [12]
0.9 ± 0.1  10-9
[3H]-Nisoxetine in vitro binding
human transfected cells [12]
7.8 ± 0.4  10-7
5-HT: 5-Hydroxytryptamine; Ki: Mean of affinity constants expressed in
M ± S.E.M. (standard error of the mean).
Table 2. Fluoxetine affinities for various
neurotransmitter receptors.
Receptors affinity IC50 (nM)
5-HT1A 79,000
5-HT2A 710
5-HT2C 160
Dopamine D1 10,000
Dopamine D2 32,000
a1-adrenergic 14,000
a2-adrenergic 2800
b-adrenergic 18,000
Cholinergic muscarinic 3100
Histamine H1 3200
5-HT: 5-Hydroxytryptamine.
L. Perez-Caballero et al.
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proposed to explain the persistent changes of extracellular
5-HT after chronic fluoxetine treatment. Microdialysis and
electrophysiology studies support the desensitisation of raphe
somatodendritic 5-HT1A autoreceptors [19,33,36] that nega-
tively regulate the release of 5-HT in terminal areas [37].
Through radioligand-binding assay and autoradiographic
quantification, it was revealed that the ability of fluoxetine
to downregulate the density of these autoreceptors might
explain this altered sensitivity, although this hypothesis
remains somewhat controversial [36,38-40]. However, it has
also been suggested that the desensitisation of 5-HT1A autor-
eceptors may be due to alterations in their signal
transduction, which involves G-protein [39,41].
Furthermore, there is evidence that the persistent increase in
extracellular 5-HT induced by chronic fluoxetine might be
explained by the desensitisation of terminal 5-HT1B autorecep-
tors, whose activation exerts a feedback inhibition of 5-HT
release, as demonstrated by electrophysiology and microdialysis
assays [42,43]. Accordingly, the support for fluoxetine-induced
5-HT1B subsensitivity came from the decrease in receptor
expression observed [44], although other reports did not confirm
this effect [36,45]. Other explanations of the mechanism of action
of fluoxetine after long-term treatment have also been proposed.
For example, the role of other 5-HT receptors has been evoked,
given that chronic fluoxetine treatment also downregulates
the density of 5-HT4 receptors and produces a functional
desensitisation involving the adenylate cyclase system [46]. By
contrast, long-term treatment does not provoke robust altera-
tions in other 5-HT receptors, such as 5-HT2 or 5-HT3
[45,47,48]. In addition, there is some controversy regarding the
role of 5-HT transporters in the adaptive changes following
chronic fluoxetine administration [36,38,44].
Chronic fluoxetine administration did not produce
adaptive changes or downregulation of other neurotransmitter
receptors (opioids, adrenergic, muscarinic or histamine
H1 receptors) [40,47,48]. This favours possible advantages in
the long-term treatment with fluoxetine because this
compound will be less cardiotoxic than TCAs, with fewer
anticholinergic and antihistaminergic side effects [11,13,40]. As
the adaptive changes described above must be produced, it
is widely accepted that chronic fluoxetine treatment is neces-
sary to obtain a therapeutic effect. In this way, preclinical
data suggest that can be used strategies based on fluoxetine
treatment in combination with antagonists of the 5-HT
desensitised receptors after long-term treatment to accelerate
the clinical action of fluoxetine and even to improve its
antidepressant efficacy [22,43,46,49].
On the other hand, novel mechanisms of action have
been proposed to elucidate the underlying bases of the antide-
pressant effect of fluoxetine. Recently, it has been described
that fluoxetine induces epigenetic modifications that may
contribute to the therapeutic action of this antidepressant.
In this way, modifications in levels of acetylated histones [50]
as well as altering the expression of some microRNAs
(miRNAs) in several brain areas [51,52] have been related to
depressive pathology. Thus, chronic fluoxetine treatment
is able to reverse some of these changes and interestingly,
these miRNAs alterations are also reversed by the non-
pharmacological electroconvulsive therapy [52]. Even more,
other new mechanisms have been proposed for this antidepres-
sant, for example a recent study involves a chromatin-
remodelling factor in the antidepressant effect of fluoxetine [53].
Overall, the mechanism of action of this compound could open
an avenue for understanding. However, further research is
required to explain whether these epigenetic changes are directly
related to the antidepressant effect of fluoxetine.
5. Neuroplasticity
5.1 Neurotrophins and synaptic plasticity
Neurotrophins are growth factors that critically regulate the for-
mation and plasticity of neuronal networks. The neurotrophic
hypothesis of depression postulates that a reduction in the
neurotrophin brain-derived neurotrophic factor (BDNF) levels
in the brain predisposes an individual to depression, whereas
antidepressant activity induces an increase in BDNF [54].
Given the antidepressant effect of fluoxetine, several neuro-
trophic factors have been evaluated after single and chronic
administrations of this compound. Accordingly, fluoxetine
has been shown to have a ‘biphasic’ effect on BDNF transcrip-
tion, first inducing its downregulation 4 h after acute or chronic
treatment and subsequently provoking an increase at 24 h, only
after long-term treatment [55,56]. Along similar lines, both acute
and chronic fluoxetine treatments enhance the phosphorylation
of the BDNF receptor, tropomyosin related kinase B (TrkB),
suggesting an increase in BDNF release that may lead to a
decrease in its transcription [57]. In addition, chronic fluoxetine
administration also increases the cAMP-related element bind-
ing protein in the hippocampus, a major transcription factor
directing gene expression of plasticity-related molecules, such
as BDNF or TrkB receptor [58,59]. Although the most common
neurotrophic factor that has been studied is BDNF, other neu-
rotrophic factors have also been evaluated. For example, there is
evidence of an increase in the vascular endothelial growth factor
and basic fibroblast growth factor 2 in hippocampal neurons
after chronic but not acute fluoxetine treatment [60,61], which
may maintain a close relationship with neuroplasticity and cel-
lular adaptation. It is noteworthy that fluoxetine also increases
synaptic plasticity, which might improve the reorganisation of
neuronal circuits and induce a clinically beneficial effect [62,63].
5.2 Adult neurogenesis
Several lines of evidence indicate that neurotrophic factors are
closely linked to adult neurogenesis and plasticity, processes
that are impaired during the course of depression. Indeed, it
has been demonstrated that antidepressants have the capacity
to regulate new cell birth and survival [64]. Accordingly,
chronic fluoxetine treatment enhanced neurogenesis in the
hippocampal subgranular zone and it has also been shown
Fluoxetine
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to increase cell proliferation and the long-term survival of the
newborn granule neurons [57,59,61,64].
6. Preclinical studies of fluoxetine
Due to the effect of fluoxetine on serotoninergic neurotrans-
mission, many preclinical studies have demonstrated its antide-
pressant effect in several animal model of depression, including
pharmacological models (reserpine), the forced swimming test
(FST), chronic mild stress (CMS), learned helplessness (LH),
olfactory bulbectomy (OB), as well as assessing its effect on
anxiety, cognition and others processes. In general, the inhibi-
tion of 5-HT reuptake mediated by fluoxetine reduces food
intake and consequently body weight [65], foot-shock induced
aggression [66], sexual behaviour [67] and it produces potent
antidepressant effects that are described in more detail below.
6.1 Effect on depressive-like behaviour
The antidepressant activity of fluoxetine as an SSRI is well
established, and furthermore, it is currently being used to
validate animal models of depression [68]. Nevertheless, it is
important to note that there are some predictive models of
depression that do not respond to SSRI, at least, following
acute administration.
Early pharmacological studies regarding the antidepressant
effect of fluoxetine showed a potentiation of the 5-hydroxy-
tryptophan-induced suppression of operant response [69],
probably due to its 5-HT selective profile. By contrast,
fluoxetine was ineffective in reversing hypothermia in the
pharmacological model of reserpine [70]. In 1995, studies
using animal models of depression (such as LH) showed
that chronic administration of fluoxetine significantly pre-
vented the behavioural escape deficits produced by the
repeated exposition to unpredictable shocks [71].
Conversely, the antidepressant activity of fluoxetine has
been demonstrated widely in the FST, a test of antidepressant
activity where immobility represents ‘behavioural despair’, a
classical depressive-like behaviour. Studies using the FST
suggest that increased serotoninergic neurotransmission is
involved with enhanced swimming behaviour and not only
does fluoxetine enhance swimming behaviour, as an SSRI it
also decreases the immobility time [72]. These effects in the
FST have been observed after both acute- (three times 24 h
prior to test) and chronic-term (over 14 -- 21 days) adminis-
trations but not after subchronic (3 days) treatment. More-
over, these effects on immobility and swimming behaviour
were mainly observed in Sprague--Dawley rats and BALB/c
mice [73,74]. By contrast, Wistar Kyoto rats, and C57BL/6
and 129SvEv mice, are resistant to the effects of fluoxetine
in the FST paradigm [74,75]. Thus, the antidepressant effect
of fluoxetine in the FST seems to be strain-dependent,
probably due to the genetic background of each strain.
Hence, identifying the genes associated with resistance to
fluoxetine treatment will be interesting to understand the
pathophysiology of depression.
Disturbances in the rapid eye movement (REM) phase of
sleep are characteristic of depressive patients, and it has been
demonstrated that chronic administration of fluoxetine can
improve this defect [76]. Interestingly, similar findings were
obtained in preclinical research, where both acute [77] and
chronic administrations of fluoxetine were effective in
decreasing REM sleep in rodents [78].
The antidepressant efficacy of fluoxetine has been also
tested in CMS. CMS-induced depressive-like behaviour has
been seen to be reversed by chronic treatment with fluoxetine.
Indeed, anhedonia, a core symptom of MDD, was reversed
after long-term fluoxetine treatment in chronically stressed
rats [79]. Moreover, secondary effects associated with the
CMS model, such as cardiovascular impairments, were also
reversed by chronic administration with fluoxetine [79], sug-
gesting that the treatment of MDD with this antidepressant
could be appropriate in cardiac depressed patients.
Additionally, fluoxetine has been used in other animal
models of depression, including that involving the bilateral
lesion of the olfactory bulb. OB has been characterised as induc-
ing behavioural and neurochemical changes related to clinical
depression, such as motor agitation, cognitive impairment,
noradrenergic and serotoninergic dysfunctions [80]. Interest-
ingly, it has been demonstrated that OB-induced depressive
behaviour is reversed after chronic fluoxetine administration [81].
Furthermore, it was demonstrated that fluoxetine normalised
OB-induced hyperactivity and that it reversed the physiological
parameters associated with this model of depression, such as the
altered heart rate and body temperature [82].
6.2 Effect on anxiety-like behaviour
As increases in 5-HT have been associated with anxiety, the
effect of fluoxetine on this phenomenon has been studied.
Most studies into anxiety have demonstrated that acute
administration of fluoxetine provokes an anxiogenic-like
effect in the elevated plus maze [83,84], a clinical effect typical
of the first-phase of fluoxetine treatment. However, studies
on chronic administration of fluoxetine have been inconclu-
sive. Although any or anxiogenic effects have been demon-
strated in Wistar and Sprague--Dawley rats [83-85], a clear
anxiolytic effect was seen in the open field, as well as
novelty-induced hypophagia, in BALB/cJ mice [74]. By con-
trast, in Wistar Kyoto rats, the anxiolytic-like effect after acute
administration became a tendency toward an anxiogenic-like
effect after chronic administration of fluoxetine [75]. Thus, as
mentioned above, the effect of fluoxetine on anxiety-like
behaviour also seems to be strain dependent.
6.3 Effect on cognition
Cognitive process, including learning and memory, are also
events that might be affected by the treatment with fluoxetine.
Initial studies demonstrated that fluoxetine improved consol-
idation and retrieval memory in mice [86], yet subsequently, it
was shown that acute administration of fluoxetine (5 and
10 mg/kg, 24 h prior to testing) improved the conditioned
L. Perez-Caballero et al.
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response to a unconditioned stimulus in a dose-dependent
manner [87]. However, subsequent studies produced some
uncertainty regarding the effect of fluoxetine on memory.
On the one hand, chronic administration of low doses of
fluoxetine (0.7 mg/kg once daily for 28 days) in adult rats
did not affect learning and short-term memory, but rather it
impaired long-term memory [88]; on the other hand, in ado-
lescent rats subchronic fluoxetine treatment induced cognitive
deficits evident in the Morris water maze [89]. These contra-
dictory results could be explained due to different ages tested,
and indeed, cognitive deficits have been detected in clinical
trials on adolescent patients treated with fluoxetine [90].
Additionally, it is important to note that chronic but not
acute administration of fluoxetine increases neurogenesis and
improves cognition in adult rodents [64]. The effect of chronic
fluoxetine administration on neuroplasticity could explain the
underlying antidepressant effects exerted by this compound.
Neuroplastic changes require several weeks to be effective,
and interestingly, the same time frame was necessary for the
recovery of depressed patients after treatment with this
antidepressant.
6.4 Other preclinical studies
Although most preclinical studies on fluoxetine have focused
on depression, 5-HT neurotransmission is also involved in
many physiological processes like food intake, aggression,
sleep, sexual behaviour, body temperature, fear, vomiting
and so on. Thus, the 5-HT reuptake inhibition mediated by
fluoxetine is also likely to be effective in animal models of
obsessive--compulsive disorder (OCD) [91], panic-like behav-
iour [92], as well as in bulimia and anorexia nervosa [93].
Indeed, this drug was observed to be effective in pulmonary
vascular remodelling induced by methamphetamine [94] and
in relieving premenstrual syndrome [95]. However, like other
findings with SSRI, fluoxetine had no effect reversing
pain-related behaviours [96].
7. A reflection on the first clinical studies
validating the antidepressant effects of
fluoxetine
After numerous preclinical studies demonstrated the efficacy
of fluoxetine as a potent antidepressant [71-74,79,81], this
compound was tested in patients suffering from depression.
In one of the first human studies, the clinical efficacy and
safety of fluoxetine was compared with imipramine in a dou-
ble-blind, 5-week, parallel study performed on 40 depressed
out-patients. This study established that fluoxetine is an
effective antidepressant with fewer and less troublesome side
effects than imipramine [3]. Furthermore, one of the first stud-
ies comparing fluoxetine to amitriptyline, another TCA, was
carried out in 1985 [97]. In 1985, the efficacy of fluoxetine
in OCD was published, a mental status that at that time
was treated with chlorimipramine [98]. Up to 1988, the
efficacy and security of fluoxetine had always been compared
to that of TCAs, until a review compared the effectiveness of
fluoxetine with that of other antidepressants with similar SSRI
properties, some of that no longer exist, such as zimelidine [99].
The conclusion was that these compounds were useful to treat
not only depression but also anxiety. One of the adverse
effects attributed to TCAs are the cardiovascular side effects.
In this sense, the safety of fluoxetine was demonstrated in
comparison to amitriptyline and many other studies were
published in the 1980s on the efficacy and safety of fluoxe-
tine. In function of the dose administered and the treatment
time, as well as the type of patient, in these studies fluoxetine
emerged as an effective, safe and easy to use antidepressant.
Indeed, over the years, it has become the antidepressant of
choice in primary care [100], although not all patients reach
the desired therapeutic effect being the response rate up
to 50%. This percentage could be because depression is a
multifactorial disease and changes in genetic, biochemical,
neuroanatomic or psychological factors as well as different
symptomatology may be responsible for a variation of
treatment response pattern among patients.
8. Conclusion
In the present review, we briefly describe the development and
clinical applications of fluoxetine, one of the first SSRI antide-
pressants. This compound augments the extracellular levels of
5-HT, accompanied by a decrease in both its synthesis and
turnover. Fluoxetine induces several adaptive changes after
long-term treatment, including the desensitisation of some
5-HT receptors, and an increase in synaptic plasticity and
adult hippocampal neurogenesis. This drug did not show
greater affinity for other reuptake transporters (noradrenaline
and dopamine), and it has no effect on noradrenergic, hista-
minergic or cholinergic receptors. The preclinical literature
reviewed demonstrates its antidepressant effect in several
animal models of depression and anxiety, as well as its effect
on cognition.
For years, fluoxetine has been the first-line treatment for
depression, a mental disorder that affects > 350 million people
of all ages. Moreover, fluoxetine is also useful for the treat-
ment of other mental disorders, such as anxiety or OCD, in
addition to anorexia or bulimia, among others. Finally, fluox-
etine is probably the best studied antidepressant in the twen-
tieth century, a period known as ‘The Prozac (fluoxetine) era’.
9. Expert opinion
For years, the treatment of depression has been a challenge for
neuroscientists and psychopharmacologists. The new scientific
era of the psychopharmacology of depression commenced
when the monoamine hypothesis of depression was postulated,
and it was further consolidated through seminal experimental
findings and well-designed clinical trials. This also represents
the onset of the use of MAOI and TCA antidepressants as
Fluoxetine
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keystone treatments for depression. However, by 1980, a new
and innovative antidepressant had been designed and launched
by Lilly, named fluoxetine. It should not be forgotten that the
significant advances that have occurred in the development of
new antidepressant drugs would not have been possible without
the development and validation of new animal models of
depression, with predictive validity. However, should bear in
mind that animal models of depression widely used are based
on the detection of drugs whose mechanism of action consists
of increasing monoamine neurotransmission for instance
TCA. In this way, it is a limitation for research of new antide-
pressant compounds due to only the compounds with a positive
response in these models will be considered with antidepressant
activity. Thus, drugs with potential antidepressant effect medi-
ated by a non-monoaminergic mechanism of action could be
discarded. Indeed, fluoxetine as well as other antidepressants
may have contributed to stall the development of new models
of depression.
Fluoxetine was first erroneously considered the ‘moitie’ of a
TCA. In fact, in contrast to many TCAs, fluoxetine not ‘only’
inhibits the 5-HT reuptake but also, an added advantage was
that fluoxetine does not block histaminergic, cholinergic and
a-adrenergic receptors. Thus, fluoxetine was devoid of effects
on blood pressure and had a better profile of undesirable
effects. The success of fluoxetine in clinical setting lead to
the hypothesis that tackling serotoninergic neurotransmission
was sufficient to produce a satisfactory antidepressant effect
avoiding the side effects associated with TCAs. Since this
‘discovery’, the serotonergic hypothesis of depression became
the foremost hypothesis in this field. The logical
consequence was that the pharmaceutical industry activated
the development of ‘me too’ drugs, those similar to fluoxetine.
This is not completely true, as some SSRI were studied
prior to fluoxetine, although fluoxetine was the first to be
recognised as a selective inhibitor of 5-HT reuptake.
Nowadays, there are a series of SSRI that are as effective as
fluoxetine, with very few pharmacological differences among
them.
Fluoxetine is not only an antidepressant but can also reduce
the symptomatology of various mental disorders, such as
bulimia, anorexia, anxiety, OCDs and many others. ‘Prozac’,
the brand name, was referred to as the ‘happy-pill’ and
indeed, its efficacy and relative safety, and the lack of side
effects initially described meant that fluoxetine became the
most widely used antidepressant for many years.
Fluoxetine is efficiently absorbed from the gastrointestinal
tract after oral administration, and the long half-life contrib-
uted to it acceptance. Fluoxetine was, and is, extensively stud-
ied in practically all models of mental disorders available in
preclinical research, and it has also been studied in other
psychiatric conditions in addition to depression.
According to new research and new experimental findings,
we now know that fluoxetine is also able to enhance the avail-
ability of neurotrophic factors. These effects of fluoxetine led
to postulate that depression might be a degenerative process.
In fact, neuroimaging studies and neurochemical findings
have demonstrated that fluoxetine can aid the recovery from
the loss of neurons, even inducing adult neurogenesis. This
opens new avenues for the psychopharmacology of fluoxetine,
as well as for the development of novel antidepressants with
new mechanism of actions, better efficacy and fewer side
effects.
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